although responses lasted a median of 10 weeks ( range 4-37 ) , our data indicate that mitoxantrone , at the doses and schedules used , is an effective drug in malignant , doxorubicin-resistant lymphomas .
C0026259
mitoxantrone
C0024299
malignant